Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.

TEVA has been the subject of several other reports. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 price objective on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a report on Thursday, June 22nd. Vetr upgraded Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price objective on the stock in a report on Monday, July 24th. Zacks Investment Research upgraded Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, UBS AG cut Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating in a report on Thursday, August 3rd. Two equities research analysts have rated the stock with a sell rating, twenty-one have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $39.19.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down 0.081% during mid-day trading on Tuesday, hitting $18.575. 38,035,331 shares of the stock were exchanged. Teva Pharmaceutical Industries Limited has a 12-month low of $18.28 and a 12-month high of $55.45. The stock has a market capitalization of $18.87 billion, a P/E ratio of 238.141 and a beta of 0.46. The firm has a 50-day moving average price of $32.05 and a 200-day moving average price of $32.28.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by $0.07. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.25 earnings per share. Equities analysts predict that Teva Pharmaceutical Industries Limited will post $4.44 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/08/08/teva-pharmaceutical-industries-limited-nyseteva-downgraded-by-bidaskclub.html.

Several large investors have recently modified their holdings of TEVA. Guggenheim Capital LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 1.1% in the fourth quarter. Guggenheim Capital LLC now owns 40,276 shares of the company’s stock valued at $1,460,000 after buying an additional 446 shares during the last quarter. Teachers Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries Limited during the fourth quarter valued at $21,946,000. Chevy Chase Trust Holdings Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 3.4% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 6,273 shares of the company’s stock valued at $201,000 after buying an additional 207 shares during the last quarter. Manning & Napier Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 15.0% in the first quarter. Manning & Napier Advisors LLC now owns 96,678 shares of the company’s stock valued at $3,101,000 after buying an additional 12,645 shares during the last quarter. Finally, Country Club Trust Company n.a. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 5.7% in the first quarter. Country Club Trust Company n.a. now owns 164,839 shares of the company’s stock valued at $5,290,000 after buying an additional 8,870 shares during the last quarter. 56.27% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.